Medical Expulsive Therapy: A 4-Millimeter Stone and an 8-Millimeter Stone
Two patients with distal ureteral stones, one on each side of the five-millimeter line the largest tamsulosin trials disagree about — and a genuinely different answer for each of them.
Diego M., a 41-year-old man, has driven for a regional courier service for six years, covering a rotating route that keeps him behind the wheel eight to ten hours most days. Around midnight two nights ago he woke with sharp, colicky left flank pain radiating toward his groin — sharp enough that he pulled over rather than finish the drive home. Non-contrast CT in the emergency department confirmed a 4mm stone lodged in the distal left ureter with mild upstream hydronephrosis, no fever, no leukocytosis, and a creatinine of 0.9 — a straightforward obstructing stone, not an infected or high-grade one. He has never had a kidney stone before, drinks little water on shift because bathroom breaks are hard to schedule into his route, and has no other chronic medical problems; today's vitals and labs are otherwise unremarkable.
His pain is well controlled on an as-needed NSAID, and at 4mm the working assumption is that he will not need an intervention — most stones this size pass on their own within a few weeks. The actual question in front of the team is narrower than it looks: does adding tamsulosin, the reflexive next step for years, actually shorten that wait, or does it add a real side-effect burden to a patient whose job depends on staying upright and alert for most of his waking hours? SUSPEND, the largest placebo-controlled trial of medical expulsive therapy, randomized 1,167 patients and stratified allocation by stone size at exactly the ≤5mm/>5mm line Diego's stone falls on the small side of — and found no significant difference in unassisted clearance between tamsulosin, nifedipine, and placebo in that stratum.
Tamsulosin's proposed benefit works through alpha-1 receptor antagonism relaxing ureteral smooth muscle, concentrated most heavily in the distal ureter near the point where it crosses the bladder wall — the same narrow segment where most stones eventually lodge regardless of their overall size. One plausible reading of the size-dependent trial results is mechanical: a 4mm stone may already be small enough to negotiate that bottleneck passively, with or without additional smooth-muscle relaxation, while a larger stone might genuinely depend on the drug's effect to clear the same anatomic point. That is a physiological argument, not a trial finding, and it cannot do the work SUSPEND's own data declined to do — at 4mm it predicts exactly the null the trial reported, which is a reason to distrust it as an argument for the drug rather than a reason to reach for one.
SUSPEND is a real result, but it is one trial against a larger meta-analytic literature that still shows a pooled benefit for distal stones, and AUA's own panel — fully aware of SUSPEND when it last updated — kept alpha-blockers as an option to offer rather than removing them. I'd start tamsulosin now. It is inexpensive, generally well tolerated, and gives him one more thing working in his favor while he waits this out.
I want to be precise about what SUSPEND actually tested, because it matters here specifically. Stone size wasn't an afterthought in that trial — it was a prespecified minimization variable, randomization stratified at exactly ≤5mm versus >5mm, so the null result in the smaller stratum isn't a subgroup fished out after the fact. Diego's stone sits inside the stratum where the trial found nothing.
A pooled meta-analytic signal is built by averaging across every stone size in the literature, including larger stones where a real effect probably exists — that's not the same claim as "tamsulosin helps a 4mm stone." And the drug isn't free of cost here: orthostatic hypotension is a labeled, mechanism-based effect of alpha-1 blockade, and for a man who spends most of his day upright behind the wheel, a dizzy spell on the job is not an abstract risk.
I don't think we have to settle whose reading of the trial literature is right today. His pain is controlled, there's no fever, no worsening obstruction, nothing that forces an irreversible choice on this visit. Reassess with a follow-up scan in one to two weeks and let his own stone's actual trajectory answer the question, rather than deciding it in advance from population data that disagrees with itself depending on how you average it.
Agreed: no tamsulosin today. Follow-up imaging in one to two weeks will show whether the stone has moved, and the drug question can be revisited then on the strength of his own trajectory rather than a contested population estimate.
Not agreed: whether AUA's continued conditional endorsement of alpha-blockers should still apply to a patient who falls inside the exact stratum SUSPEND tested and found nothing in. The urologist and the clinical pharmacologist left that question open rather than resolve it in either direction.
Aisha R., a 52-year-old woman, has lived with and cared for her mother, who has advanced dementia, for the past three years — a routine of medication schedules, meals, and near-constant supervision that leaves little room for anything unpredictable. She came to the emergency department two days ago with right flank pain radiating to her groin that had built steadily over about eighteen hours, unlike a brief episode of discomfort she'd had once before and never followed up on. Non-contrast CT confirmed an 8mm stone impacted in the distal right ureter with moderate hydronephrosis; her creatinine today, 0.9, matches her own baseline from a visit two years ago, and she has no fever or signs of infection. She has well-controlled hypothyroidism on levothyroxine and is otherwise healthy — a baseline that matters here mainly for what it rules out rather than what it explains.
At 8mm, the numbers work against her regardless of what happens next: published spontaneous passage rates for distal stones this size remain well under half even with medical therapy, a baseline the team has to state plainly before any drug enters the conversation. Ye and colleagues' multicenter trial, the largest of its kind at 3,296 analyzed patients with distal ureteral stones, found tamsulosin raised overall expulsion from 79% to 86% — and its subgroup analysis of stones over 5mm, the range Aisha's falls in, showed the benefit holding on its own rather than as an artifact of averaging in smaller stones that make up most of ureteral colic; in the same analysis, stones of 5mm or less showed no benefit at all, which is where Diego's sits. That is the opposite of what SUSPEND found two beds over for a smaller stone: the same drug, tested in overlapping but not identical populations, reads differently depending on which side of five millimeters a patient's stone happens to sit.
There is a further boundary worth naming honestly: separate endourology literature generally stops recommending an observation trial at all once a stone reaches roughly 10mm, since spontaneous passage above that size becomes rare enough that most guidelines default straight to intervention. At 8mm Aisha sits inside the window where the drug has its best evidence and near the edge where observation stops being offered at all — close enough to that edge that whatever is tried has to be tried on a clock, not open-endedly.
Ye's own prespecified subgroup analysis for stones over 5mm is not a post-hoc convenience slice — it's the population her stone actually sits in, not near its margin. I'd offer a defined trial of tamsulosin now, with a clear window in mind, rather than treat her stone as automatically a surgical one just because it's larger than the stone in the next room.
I take the subgroup result seriously, but even inside that favorable subgroup, spontaneous passage at 8mm stays a minority outcome. Layer onto that the fact that Aisha cannot easily plan around an unpredictable colic flare while she's caring for her mother — an unscheduled emergency department visit isn't a minor inconvenience for her the way it might be for someone else. I'd rather book a ureteroscopy now and give her a date she can plan around.
A trial-supported drug is still a bet on an outcome the same trial says is a minority even when it works — that's a real distinction from a stone where the drug's benefit is the whole story.
I know Aisha well enough to say she would rather try to avoid a procedure if there's a real chance of it, and Ye's trial gives her a real chance, not a token one. I'd propose splitting the difference honestly rather than picking a side: start tamsulosin with an explicit two-week deadline, and book the ureteroscopy slot today as a backup rather than waiting to see if she needs it. She keeps her preference and we don't lose the scheduling advantage of booking early.
Agreed: a two-week trial of tamsulosin, with a ureteroscopy slot already reserved so a decision to proceed doesn't cost her another wait for scheduling.
Not agreed: the endourologist went along with the plan mainly because Aisha herself preferred to try first, not because the baseline passage probability at 8mm had changed his own read of where the odds sit.